Surmodics Stock Alpha and Beta Analysis
| SRDX Stock | USD 42.98 0.00 0.00% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as SurModics. It also helps investors analyze the systematic and unsystematic risks associated with investing in SurModics over a specified time horizon. Remember, high SurModics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to SurModics' market risk premium analysis include:
Beta (0.55) | Alpha 0.53 | Risk 7.55 | Sharpe Ratio 0.14 | Expected Return 1.02 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
SurModics | Build AI portfolio with SurModics Stock |
SurModics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. SurModics market risk premium is the additional return an investor will receive from holding SurModics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in SurModics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate SurModics' performance over market.| α | 0.53 | β | -0.55 |
SurModics Fundamentals Vs Peers
Comparing SurModics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze SurModics' direct or indirect competition across all of the common fundamentals between SurModics and the related equities. This way, we can detect undervalued stocks with similar characteristics as SurModics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of SurModics' fundamental indicators could also be used in its relative valuation, which is a method of valuing SurModics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare SurModics to competition |
| Fundamentals | SurModics | Peer Average |
| Return On Equity | -0.15 | -0.31 |
| Return On Asset | -0.0052 | -0.14 |
| Profit Margin | (0.15) % | (1.27) % |
| Operating Margin | 0 % | (5.51) % |
| Current Valuation | 614.37 M | 16.62 B |
| Shares Outstanding | 14.3 M | 571.82 M |
| Shares Owned By Insiders | 3.40 % | 10.09 % |
SurModics Opportunities
SurModics Return and Market Media
The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Alliancebernstein L.P. Has 25.93 Million Position in Surmodics, Inc. SRDX - MarketBeat | 09/12/2025 |
2 | Surmodics reports real-world Pounce thrombectomy system findings | 10/30/2025 |
3 | Surmodics Announces PROWL Registry 160-Patient Data to be Presented in Industry-Sponsored Session at VIVA Conference on November 3 | 11/03/2025 |
4 | Surmodics Announces Outcomes from 160 Patients in PROWL Registry Evaluating Pounce Thrombectomy Platform in Treatment of Real-World Limb Ischemia Presentations | 11/04/2025 |
5 | Surmodics Acquisition by GTCR Clears Legal Hurdle - GuruFocus | 11/10/2025 |
6 | GTCR can proceed with Surmodics acquisition after court denies FTCs attempt to block it | 11/11/2025 |
7 | TriSalus Life Sciences, Inc. Reports Q3 Loss, Tops Revenue Estimates | 11/13/2025 |
8 | Surmodics Hits New 12-Month High Heres Why | 11/17/2025 |
9 | Disposition of 89127 shares by Gary Maharaj of SurModics at 33.64 subject to Rule 16b-3 | 11/19/2025 |
10 | Understanding Momentum Shifts in - news.stocktradersdaily.com | 11/26/2025 |
About SurModics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including SurModics or other stocks. Alpha measures the amount that position in SurModics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Days Sales Outstanding | 65.8 | 67.37 | 60.64 | 43.66 | PTB Ratio | 3.75 | 4.62 | 5.31 | 5.16 |
SurModics Upcoming Company Events
As portrayed in its financial statements, the presentation of SurModics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, SurModics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of SurModics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of SurModics. Please utilize our Beneish M Score to check the likelihood of SurModics' management manipulating its earnings.
| 1st of February 2024 Upcoming Quarterly Report | View | |
| 24th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of November 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of September 2023 Last Financial Announcement | View |
Build Portfolio with SurModics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for SurModics Stock Analysis
When running SurModics' price analysis, check to measure SurModics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SurModics is operating at the current time. Most of SurModics' value examination focuses on studying past and present price action to predict the probability of SurModics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SurModics' price. Additionally, you may evaluate how the addition of SurModics to your portfolios can decrease your overall portfolio volatility.